Leica Biosystems to Acquire Devicor Medical Products, Inc.

PR58863

BUFFALO GROVE, Illinois, Dec. 4 /PRN=KYODO JBN/ --

    Leica Biosystems, a global leader in anatomic pathology laboratory

solutions and instruments, announced today that it has successfully completed

its previously announced acquisition of Devicor Medical Products, Inc.

    Devicor is a global market leader in breast biopsy instruments and

consumables, with annual revenues of approximately $170 million. It is

committed to advancing technology to help clinicians accurately diagnose breast

disease, such as breast cancer, through minimally invasive procedures. Among

Devicor's products is the Original Mammotome Breast Biopsy System, which, to

date, has enabled more than four million women to have a minimally invasive

breast biopsy.

    "Leica's Biosystems' products and solutions address the key steps across

the anatomic pathology laboratory workflow. The addition of Devicor's market

leading breast biopsy products, especially Mammotome, allows us to further

integrate that workflow from the source, starting with the patient and the

biopsy sample," said Matthias Weber, MD, President of Leica Biosystems. "This

acquisition supports our mission of advancing cancer diagnostics to improve

lives by adding products that will have direct benefits for the patients and

the clinicians who care for them."

    Devicor will operate as a standalone business within Leica Biosystems and

will continue to be led by Tom Daulton, the current CEO of Devicor. No other

financial terms and conditions have been disclosed.

    About Leica Biosystems

    Leica Biosystems, is a global leader in anatomic pathology workflow

solutions and automation, striving to advance cancer diagnostics to improve

patients' lives. Leica Biosystems provides anatomic pathology laboratories and

researchers a comprehensive product range for each step in the pathology

process, from sample preparation and staining to imaging and reporting. Leica

Biosystems' easy-to-use and consistently reliable offerings help improve

workflow efficiency and diagnostic confidence. The company is represented in

over 100 countries. It has manufacturing facilities in 8 countries, sales and

service organizations in 27 countries, and a network of dealers spanning the

globe. The company is headquartered in Nussloch, Germany. Visit

http://www.LeicaBiosystems.com for more information.

    LEICA and the Leica logo are registered trademarks of Leica Microsystems IR

GmbH.

    Devicor and Mammotome are registered trademarks of Devicor, Inc.

    Contact: Diane Mielnikowski

    Phone: +1-847-821-3446

    Email: Diane.Mielnikowski@leicabiosystems.com

    SOURCE: Leica Biosystems